Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H19N3O4S |
Molecular Weight | 349.405 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
InChI
InChIKey=AVKUERGKIZMTKX-NJBDSQKTSA-N
InChI=1S/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1
Molecular Formula | C16H19N3O4S |
Molecular Weight | 349.405 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Ampicillin is a penicillin beta-lactam antibiotic. The following gram-negative and gram-positive bacteria have been shown in in vitro studies to be susceptible to ampicillin: Hemolytic and nonhemolytic streptococci, Streptococcus pneumoniae, Nonpenicillinase-producing staphylococci, Clostridium spp., B. anthracis, Listeria monocytogenes, most strains of enterococci, H. influenzae, N. gonorrhoeae, N. meningitidis, Proteus mirabilis, many strains of Salmonella, Shigella, and E. coli. Ampicillin is indicated in the treatment of bacterial meningitis, septicemia, endocarditis, urinary tract, gastrointestinal, respiratory tract infections caused by susceptible strains of the designated organisms.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 |
|||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | AMPICILLIN SODIUM Approved UseAmpicillin is indicated in the treatment of bacterial meningitis, septicemia, endocarditis, urinary tract, gastrointestinal, respiratory tracti nfections caused by susceptible strains of bacteria (Hemolytic and nonhemolytic streptococci, Streptococcus pneumoniae, Nonpenicillinase-producing staphylococci, Clostridium spp., B. anthracis, Listeria monocytogenes, most strains of enterococci, H. influenzae, N. gonorrhoeae, N. meningitidis, Proteus mirabilis, many strains of Salmonella, Shigella, and E. coli.) |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15.04 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20399996 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: PROBENECID |
AMPICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
129.5 μg/mL |
2000 mg single, intravenous dose: 2000 mg route of administration: Intravenous experiment type: SINGLE co-administered: SULBACTAM |
AMPICILLIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
58.74 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20399996 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: PROBENECID |
AMPICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.82 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20399996 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: PROBENECID |
AMPICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1 h |
2000 mg single, intravenous dose: 2000 mg route of administration: Intravenous experiment type: SINGLE co-administered: SULBACTAM |
AMPICILLIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
72% |
AMPICILLIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
650 mg 3 times / day multiple, intravenous Studied dose Dose: 650 mg, 3 times / day Route: intravenous Route: multiple Dose: 650 mg, 3 times / day Sources: |
unhealthy, 11 to 18 months Health Status: unhealthy Age Group: 11 to 18 months Sex: M+F Sources: |
Disc. AE: Skin rash... AEs leading to discontinuation/dose reduction: Skin rash (25%) Sources: |
5 g 3 times / day multiple, intravenous Highest studied dose Dose: 5 g, 3 times / day Route: intravenous Route: multiple Dose: 5 g, 3 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: |
|
0.5 g 1 times / day single, intramuscular Recommended Dose: 0.5 g, 1 times / day Route: intramuscular Route: single Dose: 0.5 g, 1 times / day Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: |
Other AEs: Injection site pain... Other AEs: Injection site pain Sources: |
1 g 1 times / day single, intramuscular Studied dose Dose: 1 g, 1 times / day Route: intramuscular Route: single Dose: 1 g, 1 times / day Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: |
Other AEs: Injection site pain, Creatine phosphokinase increased... Other AEs: Injection site pain (grade 3-4, 100%) Sources: Creatine phosphokinase increased (100%) |
2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Sources: |
unhealthy, mean age 25.8 years Health Status: unhealthy Age Group: mean age 25.8 years Sex: M+F Sources: |
Other AEs: Injection site pain, Rash... Other AEs: Injection site pain (1%) Sources: Rash (1%) Diarrhea (5%) Fatigue (3%) Chills (1%) Headache (1%) AST increased (3%) Bilirubin increased (1%) Creatinine increased (1%) |
2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 27.1 years Health Status: unhealthy Age Group: mean age 27.1 years Sex: F Sources: |
Other AEs: Chest pain, Flatulence... Other AEs: Chest pain (5%) Sources: Flatulence (5%) Diarrhea (10%) Injection site pain (5%) |
2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 27.4 years Health Status: unhealthy Age Group: mean age 27.4 years Sex: M+F Sources: |
Other AEs: Injection site pain, Phlebitis... Other AEs: Injection site pain (0.8%) Sources: Phlebitis (5.3%) Chest pain (0.8%) Diarrhea (6.8%) Vomiting (0.8%) Retention of urine (0.8%) Rash (0.8%) Epistaxis (0.8%) Edema (0.8%) |
2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 60.1 years Health Status: unhealthy Age Group: mean age 60.1 years Sex: M+F Sources: |
Other AEs: Thrombophlebitis, Nausea... Other AEs: Thrombophlebitis (6.7%) Sources: Nausea (6.7%) Diarrhea (6.7%) Rash (6.7%) Blood eosinophils increased (6.7%) AST increased (6.7%) ALT increased (13.3%) GGT increased (13.3%) Alkaline phosphatase increased (6.7%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Skin rash | 25% Disc. AE |
650 mg 3 times / day multiple, intravenous Studied dose Dose: 650 mg, 3 times / day Route: intravenous Route: multiple Dose: 650 mg, 3 times / day Sources: |
unhealthy, 11 to 18 months Health Status: unhealthy Age Group: 11 to 18 months Sex: M+F Sources: |
Injection site pain | 0.5 g 1 times / day single, intramuscular Recommended Dose: 0.5 g, 1 times / day Route: intramuscular Route: single Dose: 0.5 g, 1 times / day Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: |
|
Creatine phosphokinase increased | 100% | 1 g 1 times / day single, intramuscular Studied dose Dose: 1 g, 1 times / day Route: intramuscular Route: single Dose: 1 g, 1 times / day Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: |
Injection site pain | grade 3-4, 100% | 1 g 1 times / day single, intramuscular Studied dose Dose: 1 g, 1 times / day Route: intramuscular Route: single Dose: 1 g, 1 times / day Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: |
Bilirubin increased | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Sources: |
unhealthy, mean age 25.8 years Health Status: unhealthy Age Group: mean age 25.8 years Sex: M+F Sources: |
Chills | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Sources: |
unhealthy, mean age 25.8 years Health Status: unhealthy Age Group: mean age 25.8 years Sex: M+F Sources: |
Creatinine increased | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Sources: |
unhealthy, mean age 25.8 years Health Status: unhealthy Age Group: mean age 25.8 years Sex: M+F Sources: |
Headache | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Sources: |
unhealthy, mean age 25.8 years Health Status: unhealthy Age Group: mean age 25.8 years Sex: M+F Sources: |
Injection site pain | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Sources: |
unhealthy, mean age 25.8 years Health Status: unhealthy Age Group: mean age 25.8 years Sex: M+F Sources: |
Rash | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Sources: |
unhealthy, mean age 25.8 years Health Status: unhealthy Age Group: mean age 25.8 years Sex: M+F Sources: |
AST increased | 3% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Sources: |
unhealthy, mean age 25.8 years Health Status: unhealthy Age Group: mean age 25.8 years Sex: M+F Sources: |
Fatigue | 3% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Sources: |
unhealthy, mean age 25.8 years Health Status: unhealthy Age Group: mean age 25.8 years Sex: M+F Sources: |
Diarrhea | 5% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Sources: |
unhealthy, mean age 25.8 years Health Status: unhealthy Age Group: mean age 25.8 years Sex: M+F Sources: |
Diarrhea | 10% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 27.1 years Health Status: unhealthy Age Group: mean age 27.1 years Sex: F Sources: |
Chest pain | 5% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 27.1 years Health Status: unhealthy Age Group: mean age 27.1 years Sex: F Sources: |
Flatulence | 5% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 27.1 years Health Status: unhealthy Age Group: mean age 27.1 years Sex: F Sources: |
Injection site pain | 5% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 27.1 years Health Status: unhealthy Age Group: mean age 27.1 years Sex: F Sources: |
Chest pain | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 27.4 years Health Status: unhealthy Age Group: mean age 27.4 years Sex: M+F Sources: |
Edema | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 27.4 years Health Status: unhealthy Age Group: mean age 27.4 years Sex: M+F Sources: |
Epistaxis | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 27.4 years Health Status: unhealthy Age Group: mean age 27.4 years Sex: M+F Sources: |
Injection site pain | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 27.4 years Health Status: unhealthy Age Group: mean age 27.4 years Sex: M+F Sources: |
Rash | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 27.4 years Health Status: unhealthy Age Group: mean age 27.4 years Sex: M+F Sources: |
Retention of urine | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 27.4 years Health Status: unhealthy Age Group: mean age 27.4 years Sex: M+F Sources: |
Vomiting | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 27.4 years Health Status: unhealthy Age Group: mean age 27.4 years Sex: M+F Sources: |
Phlebitis | 5.3% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 27.4 years Health Status: unhealthy Age Group: mean age 27.4 years Sex: M+F Sources: |
Diarrhea | 6.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 27.4 years Health Status: unhealthy Age Group: mean age 27.4 years Sex: M+F Sources: |
ALT increased | 13.3% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 60.1 years Health Status: unhealthy Age Group: mean age 60.1 years Sex: M+F Sources: |
GGT increased | 13.3% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 60.1 years Health Status: unhealthy Age Group: mean age 60.1 years Sex: M+F Sources: |
AST increased | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 60.1 years Health Status: unhealthy Age Group: mean age 60.1 years Sex: M+F Sources: |
Alkaline phosphatase increased | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 60.1 years Health Status: unhealthy Age Group: mean age 60.1 years Sex: M+F Sources: |
Blood eosinophils increased | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 60.1 years Health Status: unhealthy Age Group: mean age 60.1 years Sex: M+F Sources: |
Diarrhea | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 60.1 years Health Status: unhealthy Age Group: mean age 60.1 years Sex: M+F Sources: |
Nausea | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 60.1 years Health Status: unhealthy Age Group: mean age 60.1 years Sex: M+F Sources: |
Rash | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 60.1 years Health Status: unhealthy Age Group: mean age 60.1 years Sex: M+F Sources: |
Thrombophlebitis | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, mean age 60.1 years Health Status: unhealthy Age Group: mean age 60.1 years Sex: M+F Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 2.0 |
yes [Inhibition 1000 uM] |
PubMed
Title | Date | PubMed |
---|---|---|
Fresh vs aged benzylpenicillin on non-IgE responses in mice. | 1998 Jan |
|
A simple classification method for residual antibiotics using E. coli cells transformed by the calcium chloride method and drug resistance plasmid DNA. | 2001 |
|
Superantigen antagonist peptides. | 2001 |
|
Antibiotic susceptibility, serum response and surface properties of Klebsiella species. | 2001 |
|
Enterobacter spp. infections complicating the course of HIV disease. | 2001 Apr |
|
[Clinical characteristics of beta-lactamase negative ampicillin resistant Haemophilus influenzae (BLNAR) in respiratory tract]. | 2001 Apr |
|
Use of antibiotics to treat bacteriuria of pregnancy in the Nordic countries. Which antibiotics are appropriate to treat bacteriuria of pregnancy? | 2001 Apr |
|
Multicenter evaluation of resistance patterns of Klebsiella pneumoniae, Escherichia coli, Salmonella spp and Shigella spp isolated from clinical specimens in Brazil: RESISTNET Surveillance Program. | 2001 Feb |
|
Illegal abortions in Addis Ababa, Ethiopia. | 2001 Jan |
|
Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries. | 2001 Jan |
|
Meropenem in neonatal severe infections due to multiresistant gram-negative bacteria. | 2001 Jan |
|
Fetal and neonatal death from maternally acquired infection. | 2001 Jan |
|
Carboxydobrachium pacificum gen. nov., sp. nov., a new anaerobic, thermophilic, CO-utilizing marine bacterium from Okinawa Trough. | 2001 Jan |
|
Salmonella typhimurium-endocarditis secondary to an acquired environmental infection: a case report. | 2001 Jan |
|
Adhesion to a polymeric biomaterial affects the antibiotic resistance of Staphylococcus epidermidis. | 2001 Jan |
|
In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial. | 2001 Jan |
|
Chryseobacterium (Flavobacterium) meningosepticum outbreak associated with colonization of water taps in a neonatal intensive care unit. | 2001 Mar |
|
Factors associated with antibiotic resistance in coliform organisms from community urinary tract infection in Wales. | 2001 Mar |
|
A multicenter study of the antimicrobial susceptibility of Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis isolated from patients with community-acquired lower respiratory tract infections in 1999 in Portugal. | 2001 Spring |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/ampicillin.html
Ampicillin Dosage and Administration
This insert is for a Pharmacy Bulk Package and is intended for preparing IV admixtures only. Dosage recommendations for intramuscular or direct intravenous injection are for informational purposes only.
Infections of the respiratory tract and soft tissues.
Patients weighing 40 kg (88 lbs) or more: 250 to 500 mg every 6 hours.
Patients weighing less than 40 kg (88 lbs): 25 to 50 mg/kg/day in equally divided doses at 6- to 8- hour intervals.
Infections of the gastrointestinal and genitourinary tracts (including those caused by Neisseria gonorrhoeae in females).
Patients weighing 40 kg (88 lbs) or more: 500 mg every 6 hours.
Patients weighing less than 40 kg (88 lbs): 50 mg/kg/day in equally divided doses at 6- to 8- hour intervals.
In the treatment of chronic urinary tract and intestinal infections, frequent bacteriological and clinical appraisal is necessary. Smaller doses than those recommended above should not be used. Higher doses should be used for stubborn or severe infections. In stubborn infections, therapy may be required for several weeks. It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy.
Urethritis in males due to N. gonorrhoeae.
Adults – Two doses of 500 mg each at an interval of 8 to 12 hours. Treatment may be repeated if necessary or extended if required.
In the treatment of complications of gonorrheal urethritis, such as prostatitis and epididymitis, prolonged and intensive therapy is recommended. Cases of gonorrhea with a suspected primary lesion of syphilis should have darkfield examinations before receiving treatment. In all other cases where concomitant syphilis is suspected, monthly serological tests should be made for a minimum of four months.
The doses for the preceding infections may be given by either the intramuscular or intravenous route. A change to oral Ampicillin may be made when appropriate.
Bacterial Meningitis
Adults and children – 150 to 200 mg/kg/day in equally divided doses every 3 to 4 hours. (Treatment may be initiated with intravenous drip therapy and continued with intramuscular injections.) The doses for other infections may be given by either the intravenous or intramuscular route.
Septicemia
Adults and children – 150 to 200 mg/kg/day. Start with intravenous administration for at least three days and continue with the intramuscular route every 3 to 4 hours.
Treatment of all infections should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. A minimum of 10-days treatment is recommended for any infection caused by Group A beta-hemolytic streptococci to help prevent the occurrence of acute rheumatic fever or acute glomerulonephritis.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14195635
Ampicillin was tested in vitro for antibacterial activity against 673 clinical isolates of Gram-negative bacilli and Streptococcus faecalis. Taking the group of 673 isolates tested as a whole, 448 (67 %) were inhibited by ampicillin at a concentration of 5 ug/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:49:25 GMT 2025
by
admin
on
Mon Mar 31 17:49:25 GMT 2025
|
Record UNII |
7C782967RD
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000011281
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
WHO-VATC |
QJ51RC20
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
CFR |
21 CFR 522.90
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
LIVERTOX |
NBK547894
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
NDF-RT |
N0000011281
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
NDF-RT |
N0000011281
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
WHO-ATC |
J01CR01
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
WHO-VATC |
QJ51CA51
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
NDF-RT |
N0000011281
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
WHO-VATC |
QJ51CA01
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
CFR |
21 CFR 520.90E
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
NCI_THESAURUS |
C1500
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
WHO-VATC |
QJ01CR01
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
WHO-VATC |
QJ51CR01
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
NDF-RT |
N0000175497
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
WHO-ATC |
J01CA51
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
NDF-RT |
N0000011281
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
CFR |
21 CFR 520.90B
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
WHO-VATC |
QG51AG04
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
WHO-VATC |
QJ01CA01
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
WHO-VATC |
QJ01CA51
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
CFR |
21 CFR 520.90F
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
WHO-ATC |
S01AA19
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
NDF-RT |
N0000011281
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
IARC | Ampicillin | ||
|
WHO-VATC |
QS01AA19
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
NDF-RT |
N0000011281
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
CFR |
21 CFR 556.40
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
WHO-VATC |
QG51AG05
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.1
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
CFR |
21 CFR 520.90
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
CFR |
21 CFR 520.90D
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
NDF-RT |
N0000011281
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
NDF-RT |
N0000011281
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
WHO-ATC |
J01CA01
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
WHO-VATC |
QG51AG07
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
||
|
CFR |
21 CFR 520.90C
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB05487MIG
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
C239
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
AMPICILLIN
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
AMPICILLIN
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | Description: A white or almost white, crystalline powder; odourless or almost odourless. Solubility: Slightly soluble in water; practically insoluble in ethanol (~750 g/l) TS and ether R. Category: Antibiotic. Storage: Ampicillin should be kept in a tightly closed container, protected from light. Labelling: The designation on the container of Ampicillin should state whether the substance is in the anhydrous form or is the trihydrate. Additional information: Even in the absence of light, Ampicillin is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Definition: Ampicillin contains not less than 95.0% and not more than 102.0% of C16H19N3O4S, calculated with reference to the anhydrous substance. | ||
|
Ampicillin
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
31209
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
221058
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
DB00415
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
198
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
SUB11710MIG
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
DTXSID4022602
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
1033000
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
D000667
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
7C782967RD
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
Ampicillin and Sulbactam
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
733
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
ALTERNATIVE | |||
|
6249
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
100000092323
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
200-709-7
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
7C782967RD
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
28971
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
528986
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
m1853
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL174
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
3009
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
1339
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY | |||
|
69-53-4
Created by
admin on Mon Mar 31 17:49:25 GMT 2025 , Edited by admin on Mon Mar 31 17:49:25 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
||
|
SALT/SOLVATE -> PARENT | |||
|
BASIS OF STRENGTH->SUBSTANCE |
Ampicillin is anhydrous or contains three molecules of water of hydration
ASSAY (HPLC)
USP
|
||
|
SALT/SOLVATE -> PARENT | |||
|
ENZYME->SUBSTRATE |
Leads to resistance to the antibiotic.
|
||
|
PARENT -> DEGRADENT | |||
|
SOLVATE->ANHYDROUS | |||
|
SALT/SOLVATE -> PARENT |
For the trihydrate use about 0.1 g of the substance; the water content is not less than 120 mg/g and not more than 150 mg/g.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
PRODRUG -> METABOLITE ACTIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT | |||
|
PARENT -> IMPURITY | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
For the anhydrous form use about 0.8 g of the substance; the water content is not more than 15 mg/g.
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||